Regs.gov: Food and Drug Administration

FDA Document on Contraceptive Status Among Females 15-49

The Food and Drug Administration (FDA) has issued a document concerning contraceptive status among females aged 15-49. This notice provides information on the topic without introducing new regulatory requirements.

Hormonal Contraceptive Eligibility for Women at High HIV Risk

The FDA has issued draft guidance regarding the eligibility of hormonal contraceptives for women at high risk of HIV. This guidance aims to clarify recommendations and ensure appropriate access to contraceptive methods while considering HIV prevention strategies.

FDA Background Material on Contraceptive Use and HIV-1 Transmission Risk

The FDA has posted background material concerning contraceptive use and the risk of HIV-1 transmission. This notice provides scientific information relevant to public health discussions and regulatory considerations.

FDA Variance Application from J.M.W. Entertainment Group

The FDA has posted a variance application from The J.M.W. Entertainment Group, LLC. This document is available for review on the Regs.gov platform. No further details on the nature of the variance or its implications are provided in the notice.

FDA Acknowledgment Letter to Audio Source, Inc

The FDA has issued an acknowledgment letter to Audio Source, Inc. regarding a submission. This notice confirms receipt of the document by the agency.

FDA Complaint Document Details

The FDA has posted details regarding a complaint document, with the information made available on March 16, 2026. The document is related to a complaint filed with the agency.

FDA Glucocorticoid Receptor Gene Expression Study

The FDA has posted a study concerning Glucocorticoid Receptor gene expression. This notice is for informational purposes and does not introduce new regulatory requirements.

FDA Study on Contraceptives, Herpes, and HIV Risk

The FDA has posted a study concerning the relationship between contraceptives, herpes, and HIV risk. The study details are available through the agency's regulatory portal.

FDA Study on Oral Contraception and HIV Risk in Africa

The FDA has published a notice regarding a study on the relationship between oral contraception and HIV risk in Africa. This notice is associated with docket number FDA-2026-P-2641-0031.

FDA Progestins Classification and Pharmacology

The Food and Drug Administration (FDA) has published a document detailing the classification and pharmacology of progestins. This guidance provides information for manufacturers and pharmaceutical companies regarding these substances.